A composition comprising cannabis extract and melatonin is provided, along with formulations for delivering the composition to a subject. The composition can include a base ingredient such as polyethylene glycol, gelatin, tapioca and/or pectin； natural sweeteners； and oils of peppermint, lavender, ginger, citrus, mango, etc. The formulation can include tablets, capsules, lozenges, troches, suppositories, tinctures, a transdermal patch, a vaporizer, a metered dose inhaler, etc. The formulation avoids harmful preservatives (e.g., BHT, BHA), heavy metals and stabilizers while addressing sub-therapeutic dosing and optimizing the synergistic qualities of the ratios of the individual cannabinoids (both acidic and neutral forms), terpenes and flavonoids.
